Chicago-A biopsy of men with PSA levels of 2.6 to 4.0 ng/mL may detectorgan-confined prostate cancer more often than a biopsy in men with a PSAlevel >4.0 ng/mL, according to a large study from Washington University,St. Louis, presented yesterday. This may result in better clinical outcomes,including a lower biochemical progression rate.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.